Literature DB >> 27687741

Treatment outcomes of endoscopic resection for rectal carcinoid tumors: an analysis of the resectability and long-term results from 46 consecutive cases.

Hiroaki Kaneko1, Kingo Hirasawa2, Ryonho Koh2, Ryousuke Kobayashi2, Atsushi Kokawa2, Katsuaki Tanaka3, Shin Maeda1.   

Abstract

AIM: In Japan, most of colorectal carcinoid tumors developed in rectum. The choice of treatment is important because surgical treatment may need to construct artificial anus. Although curative endoscopic resection (ER) is desirable from the point of quality of life, sufficient evidence of endoscopic treatment for rectal carcinoid tumors is not fully obtained.
METHODS: Between April 2001 and August 2013, 46 rectal carcinoid tumors in 46 patients who underwent either with endoscopic mucosal resection with a ligation device (EMR-L) or endoscopic submucosal dissection (ESD) were analyzed retrospectively. The rates of en bloc resection, positive for lateral and/or vertical margin, curative resection, local recurrence, additional treatments, overall and disease-specific survival rate after ER were evaluated during follow-up (median observation period 61.6 months).
RESULTS: Twenty-two lesions were treated by EMR-L and 24 lesions were treated by ESD. Both groups had similar mean tumor size (EMR-L: 6.2 mm, ESD: 6.0 mm). The rate of en bloc resection, negative for both lateral and vertical margins, and curative resection were, respectively, 73%, 63%, and 50% for EMR-L, 100%, 100%, and 83% for ESD. These results suggested that the rate of resectability and curability for ESD was significantly higher than EMR-L (p < 0.05). Complications such as perforation and bleeding did not occur in both groups. Fifteen patients were judged as non-curative and 3 patients underwent additional surgery and lymph node metastasis was evident in 1 patient. Remained 11 patients were carefully followed-up, and so far no obvious recurrence was found. Thirty-two patients (84%) were eligible for long-term follow-up and 5-year overall and disease-specific survival rates were 100% and 100%, respectively.
CONCLUSION: The long-term outcomes of ER for rectal carcinoid tumors were excellent. ESD has advantage for resectability and curability compared with EMR-L; therefore, ESD is more favorable procedure as treatment for rectal carcinoid tumors.

Entities:  

Keywords:  EMR; ESD; Rectal carcinoid tumor; neuroendocrine tumor

Mesh:

Year:  2016        PMID: 27687741     DOI: 10.1080/00365521.2016.1216591

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  10 in total

1.  A novel risk-scoring system for predicting lymph node metastasis of rectal neuroendocrine tumors.

Authors:  Keigo Chida; Jun Watanabe; Kingo Hirasawa; Yoshiaki Inayama; Toshihiro Misumi; Chikara Kunisaki; Itaru Endo
Journal:  Ann Gastroenterol Surg       Date:  2020-06-10

2.  Endoscopic submucosal resection with an endoscopic variceal ligation device for the treatment of rectal neuroendocrine tumors.

Authors:  Masahide Ebi; Shoko Nakagawa; Yoshiharu Yamaguchi; Yasuhiro Tamura; Shinya Izawa; Yasutaka Hijikata; Takaya Shimura; Yasushi Funaki; Naotaka Ogasawara; Makoto Sasaki; Takashi Joh; Kunio Kasugai
Journal:  Int J Colorectal Dis       Date:  2018-08-30       Impact factor: 2.571

3.  Endoscopic management of 345 small rectal neuroendocrine tumours: A national study from the French group of endocrine tumours (GTE).

Authors:  Caroline Fine; Guillaume Roquin; Eric Terrebonne; Thierry Lecomte; Romain Coriat; Christine Do Cao; Louis de Mestier; Elise Coffin; Guillaume Cadiot; Patricia Nicolli; Vincent Lepiliez; Vincent Hautefeuille; Jeanne Ramos; Paul Girot; Sophie Dominguez; Fritz-Line V Céphise; Julien Forestier; Valérie Hervieu; Mathieu Pioche; Thomas Walter
Journal:  United European Gastroenterol J       Date:  2019-07-04       Impact factor: 4.623

4.  Pocket Creation Method of Endoscopic Submucosal Dissection to Ensure Curative Resection of Rectal Neuroendocrine Tumors.

Authors:  Ikuhiro Kobori; Yasumi Katayama; Tomoyuki Kitagawa; Yo Fujimoto; Ryosuke Oura; Koji Toyoda; Yuumi Kusano; Shinichi Ban; Masaya Tamano
Journal:  GE Port J Gastroenterol       Date:  2018-08-22

5.  Colorectal endoscopic submucosal dissection: a systematic review and meta-analysis.

Authors:  Emmanuel Akintoye; Nitin Kumar; Hiroyuki Aihara; Hala Nas; Christopher C Thompson
Journal:  Endosc Int Open       Date:  2016-09-30

6.  Local surgical excision versus endoscopic resection for rectal carcinoid: A meta-analysis.

Authors:  Qiaoqi Sui; Junzhong Lin; Jianhong Peng; Yujie Zhao; Yuxiang Deng; Zhizhong Pan
Journal:  J Cancer       Date:  2017-10-23       Impact factor: 4.207

Review 7.  Management of Gastrointestinal Neuroendocrine Tumors.

Authors:  Rongzhi Wang; Rui Zheng-Pywell; H Alexander Chen; James A Bibb; Herbert Chen; J Bart Rose
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2019-10-24

8.  Short- and long-term outcomes of endoscopic submucosal dissection for non-ampullary duodenal neuroendocrine tumors.

Authors:  Masafumi Nishio; Kingo Hirasawa; Yuichiro Ozeki; Atsushi Sawada; Ryosuke Ikeda; Takehide Fukuchi; Ryosuke Kobayashi; Makomo Makazu; Chiko Sato; Shin Maeda
Journal:  Ann Gastroenterol       Date:  2020-04-13

9.  Efficacy and safety of hybrid endoscopic submucosal dissection compared with endoscopic submucosal dissection for rectal neuroendocrine tumors and risk factors associated with incomplete endoscopic resection.

Authors:  Xiang-Yao Wang; Ning-Li Chai; En-Qiang Linghu; Hui-Kai Li; Ya-Qi Zhai; Xiu-Xue Feng; Wen-Gang Zhang; Jia-Le Zou; Long-Song Li; Jing-Yuan Xiang
Journal:  Ann Transl Med       Date:  2020-03

10.  Resectability of Rectal Neuroendocrine Tumors Using Endoscopic Mucosal Resection with a Ligation Band Device and Endoscopic Submucosal Dissection.

Authors:  Hong Kyu Lim; Seong Jun Lee; Dong Hoon Baek; Do Youn Park; Bong Eun Lee; Eun Young Park; Joon Woo Park; Gwang Ha Kim; Geun Am Song
Journal:  Gastroenterol Res Pract       Date:  2019-09-16       Impact factor: 2.260

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.